TWO YEARS ago, while serving as executive vice president in charge of separations products at Dyax, Robert Dishman realized he had to find a way to get involved in the blossoming field of proteomics. With a PhD in chemistry from the University of Massachusetts, Amherst, where he made a specialty of high-performance liquid chromatography, he could see that proteomics had the potential to contribute to speeding the timeline of drug discovery.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.